Phase 2, Phase 3 Recruiting Network
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in Oregon: - Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
- Saint Charles Health System — Bend, Oregon
- Clackamas Radiation Oncology Center — Clackamas, Oregon
- Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon
- Bay Area Hospital — Coos Bay, Oregon
Phase 2, Phase 3 Recruiting Network
This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that …
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06616584
Sites in Oregon: - Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
- Providence Newberg Medical Center — Newberg, Oregon
- Saint Alphonsus Cancer Care Center-Ontario — Ontario, Oregon
- Providence Willamette Falls Medical Center — Oregon City, Oregon
- Providence Portland Medical Center — Portland, Oregon
Phase 3 Recruiting NIH
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in Oregon: - Providence Hood River Memorial Hospital — Hood River, Oregon
- Providence Newberg Medical Center — Newberg, Oregon
- Providence Willamette Falls Medical Center — Oregon City, Oregon
- Providence Portland Medical Center — Portland, Oregon
- Providence Saint Vincent Medical Center — Portland, Oregon
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Oregon: - Clackamas Radiation Oncology Center — Clackamas, Oregon
- Legacy Mount Hood Medical Center — Gresham, Oregon
- Legacy Good Samaritan Hospital and Medical Center — Portland, Oregon
- Providence Portland Medical Center — Portland, Oregon
- Providence Saint Vincent Medical Center — Portland, Oregon
Phase 2, Phase 3 Recruiting Industry
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in Oregon: - USOR - Willamette Valley Cancer Institute and Research Center - Eugene — Eugene, Oregon
- Local Institution - 007-885B — Portland, Oregon
- Local Institution - 007-885A — Portland, Oregon
- Oregon Oncology Specialists — Salem, Oregon
- Local Institution - 007-885C — Tigard, Oregon
Phase 3 Recruiting Industry
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…
Sponsor: Pfizer
NCT ID: NCT07144280
Sites in Oregon: - OHSU Knight Cancer Institute, Beaverton — Beaverton, Oregon
- Oncology Associates of Oregon, P.C. — Eugene, Oregon
- OHSU Knight Cancer Institute, Gresham — Gresham, Oregon
- OHSU Knight Cancer Institute, Northwest — Portland, Oregon
- OHSU Knight Cancer Institute, East Portland — Portland, Oregon
Phase 3 Recruiting Industry
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Sites in Oregon: - Clinical Study Site — Eugene, Oregon
- Clinical Study Site — Portland, Oregon
Phase 3 Recruiting Industry
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if ol…
Sponsor: Eli Lilly and Company
NCT ID: NCT06890598
Sites in Oregon: - Providence Portland Medical Center — Portland, Oregon
- Providence St. Vincent Medical Center — Portland, Oregon
- Kaiser Permanente Interstate Medical Office Central — Portland, Oregon
- Oregon Health and Science University — Portland, Oregon
Phase 3 Recruiting Industry
The goal of this Phase 3 clinical trial is to study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/…
Sponsor: OncoC4, Inc.
NCT ID: NCT05671510
Sites in Oregon: - Oncology Associates of Oregon - 1138 — Eugene, Oregon
Phase 3 Recruiting Academic/Other
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Sponsor: University of Texas Southwestern Medical Center
NCT ID: NCT02468024
Sites in Oregon: - Providence Health & Services/Oregon Clinic — Portland, Oregon
Phase 2, Phase 3 Recruiting Industry
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07100080
Sites in Oregon: - Providence Cancer Institute Franz Clinic — Portland, Oregon
- Providence St. Vincent Medical Center — Portland, Oregon
- Oregon Health and Science University — Portland, Oregon
Phase 3 Recruiting Industry
Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose t…
Sponsor: Boehringer Ingelheim
NCT ID: NCT07195695
Sites in Oregon: - Providence Cancer Institute — Portland, Oregon
- Providence Cancer Institute — Portland, Oregon
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved,…
Sponsor: InSightec
NCT ID: NCT05317858
Sites in Oregon: - Oregon Health & Science University — Portland, Oregon
Phase 2 Recruiting Network
This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in Oregon: - Providence Newberg Medical Center — Newberg, Oregon
- Saint Alphonsus Cancer Care Center-Ontario — Ontario, Oregon
- Providence Willamette Falls Medical Center — Oregon City, Oregon
- Providence Portland Medical Center — Portland, Oregon
- Providence Saint Vincent Medical Center — Portland, Oregon
Phase 2 Recruiting Industry
The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-smal…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06667076
Sites in Oregon: - Oncology Associates of Oregon PC Willamette Valley Cancer Institute — Eugene, Oregon
- Oregon Health And Science University — Portland, Oregon
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in Oregon: - USOR Oncology Associates of Oregon, P.C. — Eugene, Oregon
- Compass Oncology - Rose Quarter — Portland, Oregon
Phase 2 Recruiting Industry
The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; th…
Sponsor: Johnson & Johnson Enterprise Innovation Inc.
NCT ID: NCT06667908
Sites in Oregon: - Oregon Health And Science University — Portland, Oregon
Phase 2 Recruiting Industry
This study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer for whom surgery is planned. The aim is to find out whether an investigational treatment (consisting of the immunotherapy drug cemiplimab…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06465329
Sites in Oregon: - Providence Portland Medical Center — Portland, Oregon
- University Of Nebraska Medical Center — Portland, Oregon
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06618287
Sites in Oregon: - Providence Portland Medical Center — Portland, Oregon
- Providence St. Vincent Medical Center — Portland, Oregon
- Local Institution - 0052 — Portland, Oregon
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a fi…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in Oregon: - Providence Cancer Center Oncology and Hematology Care- Eastside — Portland, Oregon
Phase 2 Recruiting Industry
Researchers want to know if intismeran autogene (the study treatment) given with pembrolizumab and chemotherapy can treat metastatic treatment-naive squamous non-small cell lung cancer (NSCLC). Intismeran autogene is designed to help a per…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07221474
Sites in Oregon: - Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0025) — Corvallis, Oregon
Phase 2 Recruiting Industry
The main goals are after treatment given before surgery, to measure the number of people who have no signs of cancer cells in tumors and lymph nodes removed during surgery; and to learn about whether the cancer gets smaller or goes away by…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06788912
Sites in Oregon: - Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8006) — Eugene, Oregon
Phase 1 Recruiting Industry
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab and BBO-10203 in subjects with locally advanced and u…
Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
NCT ID: NCT06343402
Sites in Oregon: - USOR - Oncology Associates of Oregon, P.C — Eugene, Oregon
Phase 1 Recruiting Industry
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.
Sponsor: SystImmune Inc.
NCT ID: NCT06293898
Sites in Oregon: - Providence Portland Medical Center — Portland, Oregon
Phase 1 Recruiting Industry
This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either di…
Sponsor: Nuvectis Pharma, Inc.
NCT ID: NCT05873686
Sites in Oregon: - Oregon Health and Science University — Portland, Oregon